J
Jeffrey L. Lennox
Researcher at Emory University
Publications - 95
Citations - 7717
Jeffrey L. Lennox is an academic researcher from Emory University. The author has contributed to research in topics: Viral load & Raltegravir. The author has an hindex of 42, co-authored 94 publications receiving 7236 citations. Previous affiliations of Jeffrey L. Lennox include Grady Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Roy T. Steigbigel,David A. Cooper,Princy Kumar,Joseph E. Eron,Mauro Schechter,Martin Markowitz,Mona R. Loutfy,Jeffrey L. Lennox,Jose M. Gatell,Jürgen K. Rockstroh,Christine Katlama,Patrick Yeni,Adriano Lazzarin,Bonaventura Clotet,Jing Zhao,Joshua Chen,Desmond Ryan,Rand R. Rhodes,John A. Killar,Lucinda R. Gilde,Kim M. Strohmaier,Anne R. Meibohm,Michael D. Miller,Daria J. Hazuda,Michael L. Nessly,Mark J. DiNubile,Robin Isaacs,Bach-Yen Nguyen,Hedy Teppler +28 more
TL;DR: In HIV-infected patients with limited treatment options, raltegravir plus optimization background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks.
Journal ArticleDOI
Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
Samir K. Gupta,Joseph A. Eustace,Jonathan A. Winston,Ivy I. Boydstun,Tejinder S. Ahuja,Rudolph A. Rodriguez,Karen T. Tashima,Michelle E. Roland,Nora Franceschini,Frank J. Palella,Jeffrey L. Lennox,Paul E. Klotman,Sharon Nachman,Stephen D. Hall,Lynda A. Szczech +14 more
TL;DR: This research presents a meta-analysis of the immune system’s response to Epstein-Barr virus, which has the potential to improve the quality of life of patients and reduce the likelihood of adverse events.
Journal ArticleDOI
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox,Edwin DeJesus,Adriano Lazzarin,Richard B. Pollard,José Valdez Madruga,Daniel S Berger,Jing Zhao,Xia Xu,Angela Williams-Diaz,Anthony Rodgers,Richard J. O. Barnard,Michael D. Miller,Mark J. DiNubile,Bach-Yen Nguyen,Randi Y. Leavitt,Peter Sklar +15 more
TL;DR: Raltegravir is a well tolerated alternative to efavirenz as part of a combination regimen against HIV-1 in treatment-naive patients and has rapid and potent antiretroviral activity, which was non-inferior to that of efvirenz at week 48.
Journal ArticleDOI
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
David A. Cooper,Roy T. Steigbigel,Jose M. Gatell,Jürgen K. Rockstroh,Christine Katlama,Patrick Yeni,Adriano Lazzarin,Bonaventura Clotet,Princy Kumar,Joseph E. Eron,Mauro Schechter,Martin Markowitz,Mona R. Loutfy,Jeffrey L. Lennox,Jing Zhao,Joshua Chen,Desmond Ryan,Rand R. Rhodes,John A. Killar,Lucinda R. Gilde,Kim M. Strohmaier,Anne R. Meibohm,Michael D. Miller,Daria J. Hazuda,Michael L. Nessly,Mark J. DiNubile,Robin Isaacs,Hedy Teppler,Bach-Yen Nguyen +28 more
TL;DR: When combined with an optimized background regimen in both studies, a consistently favorable treatment effect of raltegravir over placebo was shown in clinically relevant subgroups of patients, including those with baseline characteristics that typically predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low CD4 cell count, and low genotypic or phenotypic sensitivity score.
Journal ArticleDOI
Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Gregory M. Lucas,Michael W. Ross,Peter G. Stock,Michael G. Shlipak,Christina M. Wyatt,Samir K. Gupta,Mohamed G. Atta,Kara Wools-Kaloustian,Paul A. Pham,Leslie A. Bruggeman,Jeffrey L. Lennox,Patricio E. Ray,Robert C. Kalayjian +12 more
TL;DR: IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.